ArticleCardiovascular diabetology2022
Bilirubin as an indicator of cardiometabolic health: a cross-sectional analysis in the UK Biobank.
Article in Cardiovascular diabetology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 33 citations in OpenAlex.
- Article
- Association of Hyperbilirubinemia with Lipid Profile and Lipid-Related Diseases: A Large Community-Based Cohort Study.Journal of clinical medicine · 2026Article
- Polydopamine-mediated EGCG-modified polystyrene microspheres for the synergistic removal of inflammatory cytokines TNF-α and bilirubin in liver failure.Regenerative biomaterials · 2026Article
- Effect Modification by Total Bilirubin on the Association Between Hypertension and Cerebral Small Vessel Disease.Journal of stroke · 2026Article
- A Cross-sectional Data Analysis between Serum Total Bilirubin and Potential Obesity Indices in US Adults.Current molecular medicine · 2026Article
- Targeted Delivery of Bilirubin to Pulmonary Endothelium Mitigates Paraquat-Induced Lung Injury.International journal of nanomedicine · 2026Article
- Association Between Adiposity and Low Total Serum Bilirubin Concentration: A Retrospective, Cross-Sectional Study.Health science reports · 2026Article
- Bilirubin Hepatic and Intestinal Transport and Catabolism: Physiology, Pathophysiology, and Benefits.Antioxidants (Basel, Switzerland) · 2025Review
- Exploring the Impact of Urinary Metal Exposure on Blood Lipid Profiles in Chinese Adults: Mediating Roles of Health-Related Indicators.Journal of the American Heart Association · 2025Article
- Bilirubin - new insights into an old molecule.Biochemia medica · 2025Review
- The Association between Serum Lipid Profile Levels and Hypertension Grades: A Cross-Sectional Study at a Health Examination Center.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2025Article
- Investigating the impact of extreme weather events and related indicators on cardiometabolic multimorbidity.Archives of public health = Archives belges de sante publique · 2024Article
- Association between bilirubin and biomarkers of metabolic health and oxidative stress in the MARK-AGE cohort.iScience · 2024Article
- Article
- Article
- Tissue-specific genetic variation suggests distinct molecular pathways between body shape phenotypes and colorectal cancer.Science advances · 2024Article
- The association between bilirubin levels, and the incidence of metabolic syndrome and diabetes mellitus: a systematic review and meta-analysis of cohort studies.Clinical diabetes and endocrinology · 2024Review
- Mildly elevated serum bilirubin and its correlations with lipid levels among male patients undergoing health checkups.Lipids in health and disease · 2023Article
- Genetics of Plasma Bilirubin and Associations between Bilirubin and Cardiometabolic Risk Profiles in Danish Children and Adolescents.Antioxidants (Basel, Switzerland) · 2023Article
- Indirect bilirubin impairs invasion of osteosarcoma cellsJournal of bone oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 3 countries.
Funding
Abstract
backgroundMildly elevated bilirubin, a by-product of hemoglobin breakdown, might mitigate cardiometabolic risk factors including adiposity, dyslipidemia, and high blood pressure (BP). We investigated the cross-sectional relationship between (total) bilirubin and baseline cardiometabolic risk factors in 467,519 UK Biobank study participants.
methodsWe used multivariable-adjusted linear regression to estimate associations between bilirubin levels and risk factors of cardiometabolic diseases including body mass index (BMI), waist and hip circumferences (WC, HC), waist-to-hip ratio (WHR), fat mass (FM), and trunk FM, and the blood lipids: apolipoprotein A-I (apoA-I), apolipoprotein B (apoB), apoB/apoA-I, lipoprotein (a), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), LDL/HDL, TC/HDL, triglycerides (TG). Log-transformed bilirubin was modelled with restricted cubic splines and predicted mean values with 99% confidence intervals (CI) for each risk marker were estimated, separately. Second, we applied principal component analysis (PCA) for dimension reduction to in turn six anthropometric traits (height, weight, BMI, WC, HC, and WHR) and all above lipids. Last, we estimated associations (99%CI) between bilirubin and three components of the metabolic syndrome, i.e. WC, TG, and BP using logistic regression.
resultsAfter multivariable adjustments, higher levels of bilirubin were inversely associated with indicators of general adiposity (BMI and FM) and of body fat distribution (WC, HC, WHR, and trunk FM) in both men and women. For example, women with mildly elevated bilirubin (95
conclusionsHigher levels of bilirubin were inversely associated with cardiometabolic risk factors including adiposity, dyslipidemia, and hypertension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.